Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, open label, randomised, single dose, two-way crossover study in healthy volunteers to determine the pharmacokinetics of two transdermal oxymorphone patch formulations to promote pain relief

Next Previous
Trial Profile

A Phase I, open label, randomised, single dose, two-way crossover study in healthy volunteers to determine the pharmacokinetics of two transdermal oxymorphone patch formulations to promote pain relief

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxymorphone (Primary) ; Naltrexone
  • Indications Pain
  • Focus Pharmacokinetics
  • Acronyms POHO37-13
  • Sponsors Phosphagenics

    • Most Recent Events

    • 11 Aug 2014 Results published in a Phosphagenics media release.
    • 11 Aug 2014 Status changed from not yet recruiting to completed according to a Phosphagenics media release.
    • 18 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top